Kyverna Therapeutics Provides Business Update... (GlobeNewswire) - Nov 13, 2025 - "Anticipated Milestones: (i) MG: Report updated data for the Phase 2 portion of KYSA-6 Phase 2/3 trial data in 2026; Initiate enrollment for registrational Phase 3 trial by year-end 2025; (ii) Additional Indications: Lupis Nephritis: Report Phase 1 data in a peer-reviewed publication in 2026."
Clinical data • Trial status • Lupus Nephritis • Myasthenia Gravis
|